[
  {
    "ts": "2026-02-25T08:13:54+00:00",
    "headline": "Has Merck (MRK) Run Too Far After Its 41% Discount To Estimated Fair Value?",
    "summary": "If you are wondering whether Merck's share price still offers value after a strong run, you are not alone. This article is built to help you frame that question clearly. At a last close of US$123.93, Merck's stock has returned 1.9% over 7 days, 14.6% over 30 days, 16.4% year to date, 40.6% over 1 year, 27.8% over 3 years and 109.1% over 5 years. Recent attention on Merck has focused on its broader role in large cap pharmaceuticals, with investors regularly reassessing how its drug portfolio...",
    "url": "https://finance.yahoo.com/news/merck-mrk-run-too-far-081354474.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "257e67b9-0606-32da-ba22-8b47f4f8ba4b",
      "content": {
        "id": "257e67b9-0606-32da-ba22-8b47f4f8ba4b",
        "contentType": "STORY",
        "title": "Has Merck (MRK) Run Too Far After Its 41% Discount To Estimated Fair Value?",
        "description": "",
        "summary": "If you are wondering whether Merck's share price still offers value after a strong run, you are not alone. This article is built to help you frame that question clearly. At a last close of US$123.93, Merck's stock has returned 1.9% over 7 days, 14.6% over 30 days, 16.4% year to date, 40.6% over 1 year, 27.8% over 3 years and 109.1% over 5 years. Recent attention on Merck has focused on its broader role in large cap pharmaceuticals, with investors regularly reassessing how its drug portfolio...",
        "pubDate": "2026-02-25T08:13:54Z",
        "displayTime": "2026-02-25T08:13:54Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kA84g.s9IO2ClCgTX6BCgg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DmY770n7xz5DXLM6ZHLmxA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-mrk-run-too-far-081354474.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-mrk-run-too-far-081354474.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-25T09:10:00+00:00",
    "headline": "Merck & Co Digital Transformation Strategy Analysis Report 2025: Accelerators, Innovation Programs, Incubators, ICT, Technology Initiatives, Partnerships, Investments, Acquisitions, Network Map",
    "summary": "Merck's market opportunities lie in its broad biopharmaceutical offerings, targeting oncology, vaccines, and more, alongside extensive veterinary solutions. Its tech-driven innovations, strategic partnerships, and global presence enhance its competitive edge in healthcare and digital transformation initiatives.Dublin, Feb. 25, 2026 (GLOBE NEWSWIRE) -- The \"Enterprise Tech Ecosystem Series: Merck & Co., Inc. 2025\" company profile has been added to ResearchAndMarkets.com's offering. The report pro",
    "url": "https://finance.yahoo.com/news/merck-co-digital-transformation-strategy-091000757.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "0d321736-1d33-3a60-afd3-694f6bb2eca2",
      "content": {
        "id": "0d321736-1d33-3a60-afd3-694f6bb2eca2",
        "contentType": "STORY",
        "title": "Merck & Co Digital Transformation Strategy Analysis Report 2025: Accelerators, Innovation Programs, Incubators, ICT, Technology Initiatives, Partnerships, Investments, Acquisitions, Network Map",
        "description": "",
        "summary": "Merck's market opportunities lie in its broad biopharmaceutical offerings, targeting oncology, vaccines, and more, alongside extensive veterinary solutions. Its tech-driven innovations, strategic partnerships, and global presence enhance its competitive edge in healthcare and digital transformation initiatives.Dublin, Feb. 25, 2026 (GLOBE NEWSWIRE) -- The \"Enterprise Tech Ecosystem Series: Merck & Co., Inc. 2025\" company profile has been added to ResearchAndMarkets.com's offering. The report pro",
        "pubDate": "2026-02-25T09:10:00Z",
        "displayTime": "2026-02-25T09:10:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-co-digital-transformation-strategy-091000757.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-co-digital-transformation-strategy-091000757.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-25T09:26:52+00:00",
    "headline": "GSK secures potential ‘multi-blockbuster’ drug in $950mn deal",
    "summary": "GSK has reached a near-$1bn deal to acquire 35Pharma, a Canadian biotech that develops drugs for heart and lung diseases, as part of a drive...",
    "url": "https://finance.yahoo.com/news/gsk-secures-potential-multi-blockbuster-092652964.html",
    "source": "Financial Times",
    "provider": "yfinance",
    "raw": {
      "id": "636124ce-4be7-3ff3-918d-ac870ff0ddea",
      "content": {
        "id": "636124ce-4be7-3ff3-918d-ac870ff0ddea",
        "contentType": "STORY",
        "title": "GSK secures potential ‘multi-blockbuster’ drug in $950mn deal",
        "description": "",
        "summary": "GSK has reached a near-$1bn deal to acquire 35Pharma, a Canadian biotech that develops drugs for heart and lung diseases, as part of a drive...",
        "pubDate": "2026-02-25T09:26:52Z",
        "displayTime": "2026-02-25T09:26:52Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Financial Times",
          "url": "https://www.ft.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gsk-secures-potential-multi-blockbuster-092652964.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gsk-secures-potential-multi-blockbuster-092652964.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^FTSE"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-25T14:57:20+00:00",
    "headline": "Large cap pharma defensive AI winner, says RBC as it backs Lilly & AbbVie",
    "summary": "Investing.com -- RBC analysts say U.S. large cap pharma offers defensive exposure and earnings upside as artificial intelligence reshapes drug development.",
    "url": "https://finance.yahoo.com/news/large-cap-pharma-defensive-ai-145720870.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "38db119c-9f44-3acf-9b13-4ff354235b4a",
      "content": {
        "id": "38db119c-9f44-3acf-9b13-4ff354235b4a",
        "contentType": "STORY",
        "title": "Large cap pharma defensive AI winner, says RBC as it backs Lilly & AbbVie",
        "description": "",
        "summary": "Investing.com -- RBC analysts say U.S. large cap pharma offers defensive exposure and earnings upside as artificial intelligence reshapes drug development.",
        "pubDate": "2026-02-25T14:57:20Z",
        "displayTime": "2026-02-25T14:57:20Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/large-cap-pharma-defensive-ai-145720870.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/large-cap-pharma-defensive-ai-145720870.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-25T14:00:05+00:00",
    "headline": "Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock",
    "summary": "Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finance.yahoo.com/news/know-beyond-why-merck-co-140005556.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "54a1b88f-abb1-3529-a285-bd13edf69ed7",
      "content": {
        "id": "54a1b88f-abb1-3529-a285-bd13edf69ed7",
        "contentType": "STORY",
        "title": "Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock",
        "description": "",
        "summary": "Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.",
        "pubDate": "2026-02-25T14:00:05Z",
        "displayTime": "2026-02-25T14:00:05Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/d2f7ed3d1940141716bfd200f5c94c6b",
          "originalWidth": 900,
          "originalHeight": 711,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Bjs59nqcRE8iEsudL3mMxA--~B/aD03MTE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d2f7ed3d1940141716bfd200f5c94c6b.cf.webp",
              "width": 900,
              "height": 711,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Bro_swiyYm6CQ_YbyBgC9g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d2f7ed3d1940141716bfd200f5c94c6b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/know-beyond-why-merck-co-140005556.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/know-beyond-why-merck-co-140005556.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-25T13:49:00+00:00",
    "headline": "Can J&J Sustain Its Double-Digit Oncology Growth Streak?",
    "summary": "JNJ's oncology sales surged in 2025 as Darzalex and new drugs powered growth. With a $50B target by 2030, can its cancer momentum last?",
    "url": "https://finance.yahoo.com/news/j-j-sustain-double-digit-134900028.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "be5ba834-6761-3b02-a211-fbd767222d0d",
      "content": {
        "id": "be5ba834-6761-3b02-a211-fbd767222d0d",
        "contentType": "STORY",
        "title": "Can J&J Sustain Its Double-Digit Oncology Growth Streak?",
        "description": "",
        "summary": "JNJ's oncology sales surged in 2025 as Darzalex and new drugs powered growth. With a $50B target by 2030, can its cancer momentum last?",
        "pubDate": "2026-02-25T13:49:00Z",
        "displayTime": "2026-02-25T13:49:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/A9LQHlDmqgPJbKsotfjd8w--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o5.ym16dSp_UIlCHMRMZUw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/j-j-sustain-double-digit-134900028.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/j-j-sustain-double-digit-134900028.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "AZN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-25T17:37:00+00:00",
    "headline": "Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026",
    "summary": "RAHWAY, N.J., February 25, 2026--Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), a Once-Daily, Two-Drug Regimen at CROI 2026",
    "url": "https://finance.yahoo.com/news/merck-announces-breaking-data-three-173700092.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "971b28bd-941d-30a1-ba4e-690f93710d89",
      "content": {
        "id": "971b28bd-941d-30a1-ba4e-690f93710d89",
        "contentType": "STORY",
        "title": "Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026",
        "description": "",
        "summary": "RAHWAY, N.J., February 25, 2026--Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), a Once-Daily, Two-Drug Regimen at CROI 2026",
        "pubDate": "2026-02-25T17:37:00Z",
        "displayTime": "2026-02-25T17:37:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/766e424cf2726eb0ee3d1afcfdde530f",
          "originalWidth": 480,
          "originalHeight": 217,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ThACR6yJFXeEA4F.PhEokQ--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/766e424cf2726eb0ee3d1afcfdde530f.cf.webp",
              "width": 480,
              "height": 217,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lOnZ1E8T0PAtsZdtVs8C2w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/766e424cf2726eb0ee3d1afcfdde530f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-announces-breaking-data-three-173700092.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-announces-breaking-data-three-173700092.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-25T09:43:04+00:00",
    "headline": "GSK to acquire 35Pharma in $950M deal for cardiovascular drug",
    "summary": "The deal hands GSK a drug it views as a potentially “best-in-class” therapy for blood pressure diseases like pulmonary arterial hypertension — the target of Merck’s fast-selling Winrevair.",
    "url": "https://www.biopharmadive.com/news/gsk-35pharma-acquire-pulmonary-hypertension-drug-activin-winrevair/813067/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "39c4446c-7fd2-3989-b727-ed22fa23806d",
      "content": {
        "id": "39c4446c-7fd2-3989-b727-ed22fa23806d",
        "contentType": "STORY",
        "title": "GSK to acquire 35Pharma in $950M deal for cardiovascular drug",
        "description": "",
        "summary": "The deal hands GSK a drug it views as a potentially “best-in-class” therapy for blood pressure diseases like pulmonary arterial hypertension — the target of Merck’s fast-selling Winrevair.",
        "pubDate": "2026-02-25T09:43:04Z",
        "displayTime": "2026-02-25T09:43:04Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/d8db1fc0785f81e4f8e0e06a2035d2d8",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "A GSK building in London",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/u_Sv9DmBdJogo1GmDjD42A--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/d8db1fc0785f81e4f8e0e06a2035d2d8.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WhCQ20DE532zmEXnUfdSAw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/d8db1fc0785f81e4f8e0e06a2035d2d8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/gsk-35pharma-acquire-pulmonary-hypertension-drug-activin-winrevair/813067/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gsk-acquire-35pharma-950m-deal-094304242.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-25T17:38:00+00:00",
    "headline": "Merck’s New HIV Drug Shows Promise. Its Chief Medical Officer Explains Why Wall Street Should Care.",
    "summary": "Merck’s two-drug HIV regimen matched Gilead’s blockbuster Biktarvy in Phase 3 trials and is under FDA review as the company prepares for Keytruda’s patent cliff.",
    "url": "https://www.barrons.com/articles/merck-hiv-drug-islatravir-doravirine-wall-street-9c8bdd68?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "b6cace0e-a7a8-3015-9ce0-f8d15ff509ac",
      "content": {
        "id": "b6cace0e-a7a8-3015-9ce0-f8d15ff509ac",
        "contentType": "STORY",
        "title": "Merck’s New HIV Drug Shows Promise. Its Chief Medical Officer Explains Why Wall Street Should Care.",
        "description": "",
        "summary": "Merck’s two-drug HIV regimen matched Gilead’s blockbuster Biktarvy in Phase 3 trials and is under FDA review as the company prepares for Keytruda’s patent cliff.",
        "pubDate": "2026-02-25T17:38:00Z",
        "displayTime": "2026-02-25T17:38:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/b6cace0e-a7a8-3015-9ce0-f8d15ff509ac/merck%E2%80%99s-new-hiv-drug-shows.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/90d15ef755712d958b31f4c7a338b648",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/u4_cQJsJU8sh6V5CFZLpiQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/90d15ef755712d958b31f4c7a338b648.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/XLgqNEUXTraAktmiPS9siQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/90d15ef755712d958b31f4c7a338b648.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/merck-hiv-drug-islatravir-doravirine-wall-street-9c8bdd68?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-25T21:30:00+00:00",
    "headline": "FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis",
    "summary": "RAHWAY, N.J., February 25, 2026--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced today the U.S. Food and Drug Administration (FDA) approval of NUMELVI™ (atinvicitinib tablets) – the first and only second-generation Janus kinase (JAK) inhibitor indicated for the control of pruritus associated with allergic dermatitis in dogs six months of age and older. The product is expected to be a",
    "url": "https://finance.yahoo.com/news/fda-approves-numelvi-atinvicitinib-tablets-213000052.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "2f05b3e3-f477-31c9-b4f6-a91fc4f3141e",
      "content": {
        "id": "2f05b3e3-f477-31c9-b4f6-a91fc4f3141e",
        "contentType": "STORY",
        "title": "FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis",
        "description": "",
        "summary": "RAHWAY, N.J., February 25, 2026--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced today the U.S. Food and Drug Administration (FDA) approval of NUMELVI™ (atinvicitinib tablets) – the first and only second-generation Janus kinase (JAK) inhibitor indicated for the control of pruritus associated with allergic dermatitis in dogs six months of age and older. The product is expected to be a",
        "pubDate": "2026-02-25T21:30:00Z",
        "displayTime": "2026-02-25T21:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/36a941904ec0da9c42e929ba43bb8f69",
          "originalWidth": 480,
          "originalHeight": 240,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DtQCVSkisSzhqMAR5ixaVQ--~B/aD0yNDA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/36a941904ec0da9c42e929ba43bb8f69.cf.webp",
              "width": 480,
              "height": 240,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tjO2smJ17kIWAzpND5QvQA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/36a941904ec0da9c42e929ba43bb8f69.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/fda-approves-numelvi-atinvicitinib-tablets-213000052.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/fda-approves-numelvi-atinvicitinib-tablets-213000052.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-25T22:09:37+00:00",
    "headline": "Merck Reshapes Leadership As HIV And RSV Prospects Take Center Stage",
    "summary": "Merck (NYSE:MRK) announced a major reorganization of its Human Health business into two global units focused on Oncology and on Specialty, Pharma & Infectious Diseases. The company named new senior leaders to run these units, reshaping internal decision making and commercial execution. Merck reported pivotal late stage data for a new two drug HIV-1 regimen that met its non inferiority goal versus standard of care and is now under regulatory review. The company also released positive phase 3...",
    "url": "https://finance.yahoo.com/news/merck-reshapes-leadership-hiv-rsv-220937659.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "b8835962-55bf-3977-ba3d-476deb124338",
      "content": {
        "id": "b8835962-55bf-3977-ba3d-476deb124338",
        "contentType": "STORY",
        "title": "Merck Reshapes Leadership As HIV And RSV Prospects Take Center Stage",
        "description": "",
        "summary": "Merck (NYSE:MRK) announced a major reorganization of its Human Health business into two global units focused on Oncology and on Specialty, Pharma & Infectious Diseases. The company named new senior leaders to run these units, reshaping internal decision making and commercial execution. Merck reported pivotal late stage data for a new two drug HIV-1 regimen that met its non inferiority goal versus standard of care and is now under regulatory review. The company also released positive phase 3...",
        "pubDate": "2026-02-25T22:09:37Z",
        "displayTime": "2026-02-25T22:09:37Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kA84g.s9IO2ClCgTX6BCgg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DmY770n7xz5DXLM6ZHLmxA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-reshapes-leadership-hiv-rsv-220937659.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-reshapes-leadership-hiv-rsv-220937659.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]